MRC2 and prostate carcinoma: To test the hypothesis that Endo180 contributes to the plasticity of prostate cancer cell migration, PC3 cells were transfected with a scrambled control shRNA vector (PC3-shSCN) or targeted Endo180 shRNA vector (PC3-shEndo180) (Fig. 5a), which contained a previously validated siRNA oligonucleotide sequence [17, 19, 23, 24, 26, 27, 30] and was highly effective at silencing Endo180 (Fig. 5b, c).